Artiva Biotherapeutics (ARTV) Net Income towards Common Stockholders (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$35.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 4.46% year-over-year to -$35.2 million in Q1 2026; TTM through Mar 2026 was -$116.5 million, a 4.44% increase from a year earlier, with the FY2025 full-year figure at -$87.7 million, down 41.86% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$35.2 million, down from -$21.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ARTV reached as high as $11.2 million in Q3 2023 and fell as low as -$36.8 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$22.0 million across 4 years, with a median of -$23.3 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders sank 400.97% in 2024 and jumped 30.87% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$11.6 million in 2023, then tumbled by 100.05% to -$23.2 million in 2024, then climbed by 8.73% to -$21.2 million in 2025, then tumbled by 66.17% to -$35.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$35.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$23.4 million in Q3 2025.